Julien Vaubourgeix

Julien Vaubourgeix

Auto-generated profile, based on publicly available information

Julien Vaubourgeix

MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London SW7 2AZ, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2008 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
PPPascale Peyron
Pascale Peyron
JVJulien Vaubourgeix
Julien Vaubourgeix
YPYannick Poquet
Yannick Poquet
FLFlorence Levillain
Florence Levillain
CBCatherine Botanch
Catherine Botanch
FAFrédéric Altare
Frédéric Altare
Tuberculosis (TB) is characterized by a tight interplay between Mycobacterium tuberculosis and host cells within granulomas. These cellular aggregates restrict bacterial spreading, but do not kill all the bacilli, which can persist for years. In-depth investigation of M. tuberculosis interactions with granuloma-specific cell populations are needed to gain insight into mycobacterial persistence, and to better understand the physiopathology of the disease. We have analyzed the formation of foamy macrophages (FMs), a granuloma-specific cell population characterized by its high lipid content, and studied their interaction with the tubercle bacillus. Within our in vitro human granuloma model, M. tuberculosis long chain fatty acids, namely oxygenated mycolic acids (MA), triggered the differentiation of human monocyte-derived macrophages into FMs. In these cells, mycobacteria no longer replicated and switched to a dormant non-replicative state. Electron microscopy observation of M. tuberculosis–infected FMs showed that the mycobacteria-containing phagosomes migrate towards host cell lipid bodies (LB), a process which culminates with the engulfment of the bacillus into the lipid droplets and with the accumulation of lipids within the microbe. Altogether, our results suggest that oxygenated mycolic acids from M. tuberculosis play a crucial role in the differentiation of macrophages into FMs. These cells might constitute a reservoir used by the tubercle bacillus for long-term persistence within its human host, and could provide a relevant model for the screening of new antimicrobials against non-replicating persistent mycobacteria. Mycobacterium tuberculosis, the causative agent of tuberculosis, is responsible for dramatic health problems globally. It is estimated that this pathogen infects one-third of the human population and causes three million deaths annually. Most individuals remain asymptomatic for several years before developing an active disease. In such individuals, the bacilli are not cleared but rather persist in a dormant state. Major goals of TB research are to (i) understand how the bacilli remain alive for years within infected individuals, and (ii) find how to prevent their reactivation and hence clinical disease. During dormancy, most of the bacilli are confined to granulomas that consist of well-defined aggregates of different host immune cells. Granulomas prevent spreading of bacilli. In this study, we analyzed the role of a particular cell population found within granulomas, the “foamy macrophages”. These cells are filled with droplets of lipids, a well-known nutrient for persistent bacilli. We found that within these cells, the bacilli do not replicate, but remain alive and seem to internalize host lipids. The foamy macrophages might thus constitute a reservoir for persisting bacilli within their human host, and could provide a relevant model for screening of new antimicrobials against non-replicating persistent mycobacteria.

24 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SSSarah M. Schrader
Sarah M. Schrader
JVJulien Vaubourgeix
Julien Vaubourgeix
CNCarl Nathan
Carl Nathan
Improved understanding of the resistance of bacterial pathogens to antibiotics is fueling fresh approaches to identify new compounds, bacterial targets, and drug regimens.

1 February 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
JVJulien Vaubourgeix
Julien Vaubourgeix
GLGang Lin
Gang Lin
Neeraj DharNeeraj Dhar
Neeraj Dhar
NCNicolas Chenouard
Nicolas Chenouard
XJXiuju Jiang
Xiuju Jiang
CNCarl Nathan
Carl Nathan

1 November 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AGAnna E. Grzegorzewicz
Anna E. Grzegorzewicz
JKJana Kordulakova
Jana Kordulakova
VJVictoria Jones
Victoria Jones
SBSarah E. M. Born
Sarah E. M. Born
Juan BelardinelliJuan Belardinelli
Juan Belardinelli
MJMary Jackson
Mary Jackson
Isoxyl (ISO) and thiacetazone (TAC), two prodrugs once used in the clinical treatment of tuberculosis, have long been thought to abolish Mycobacterium tuberculosis (M. tuberculosis) growth through the inhibition of mycolic acid biosynthesis, but their respective targets in this pathway have remained elusive. Here we show that treating M. tuberculosis with ISO or TAC results in both cases in the accumulation of 3-hydroxy C18, C20, and C22 fatty acids, suggestive of an inhibition of the dehydratase step of the fatty-acid synthase type II elongation cycle. Consistently, overexpression of the essential hadABC genes encoding the (3R)-hydroxyacyl-acyl carrier protein dehydratases resulted in more than a 16- and 80-fold increase in the resistance of M. tuberculosis to ISO and TAC, respectively. A missense mutation in the hadA gene of spontaneous ISO- and TAC-resistant mutants was sufficient to confer upon M. tuberculosis high level resistance to both drugs. Other mutations found in hypersusceptible or resistant M. tuberculosis and Mycobacterium kansasii isolates mapped to hadC. Mutations affecting the non-essential mycolic acid methyltransferases MmaA4 and MmaA2 were also found in M. tuberculosis spontaneous ISO- and TAC-resistant mutants. That MmaA4, at least, participates in the activation of the two prodrugs as proposed earlier is not supported by our biochemical evidence. Instead and in light of the known interactions of both MmaA4 and MmaA2 with HadAB and HadBC, we propose that mutations affecting these enzymes may impact the binding of ISO and TAC to the dehydratases.

21 February 2018 in ACS Infectious Diseases
Verified
Journal Article
Open access
TLTania J. Lupoli
Tania J. Lupoli
JVJulien Vaubourgeix
Julien Vaubourgeix
KBKristin Burns-Huang
Kristin Burns-Huang
BGBen Gold
Ben Gold
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world’s deadliest infectious diseases and urgently requires new antibiotics to treat drug-resistant strains and to decrease the duration of therapy. During infection, Mtb encounters numerous stresses associated with host immunity, including hypoxia, reactive oxygen and nitrogen species, mild acidity, nutrient starvation, and metal sequestration and intoxication. The Mtb proteostasis network, composed of chaperones, proteases, and a eukaryotic-like proteasome, provides protection from stresses and chemistries of host immunity by maintaining the integrity of the mycobacterial proteome. In this review, we explore the proteostasis network as a noncanonical target for antibacterial drug discovery.

28 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
LBLaure Botella
Laure Botella
JVJulien Vaubourgeix
Julien Vaubourgeix
JLJonathan Livny
Jonathan Livny
DSDirk Schnappinger
Dirk Schnappinger
Rifampicin, which inhibits bacterial RNA polymerase, provides one of the most effective treatments for tuberculosis. Inhibition of the transcription termination factor Rho is used to treat some bacterial infections, but its importance varies across bacteria. Here we show that Rho ofMycobacterium tuberculosisfunctions to both define the 3′ ends of mRNAs and silence substantial fragments of the genome. Brief inactivation of Rho affects over 500 transcripts enriched for genes of foreign DNA elements and bacterial virulence factors. Prolonged inactivation of Rho causes extensive pervasive transcription, a genome-wide increase in antisense transcripts, and a rapid loss of viability of replicating and non-replicatingM. tuberculosis in vitroand during acute and chronic infection in mice. Collectively, these data suggest that inhibition of Rho may provide an alternative strategy to treat tuberculosis with an efficacy similar to inhibition of RNA polymerase.